Omalizumab (Xolair) in Children with Atopic Dermatitis: A Review Article
Context: Atopic dermatitis is a chronic skin disease in children. The prevalence of eczema is up to 30% in the world. Omalizumab (Xolair) is a monoclonal antibody that blocks the serum IgE. The aim of this study is to review the effect of Xolair in children with atopic dermatitis. Evidence Acquis...
Main Authors: | Javad Ghaffari, Negar Ghaffari |
---|---|
Format: | Article |
Language: | English |
Published: |
Mazandaran University of Medical Sciences
2018-01-01
|
Series: | Journal of Pediatrics Review |
Subjects: | |
Online Access: | http://jpr.mazums.ac.ir/browse.php?a_code=A-10-30-79&slc_lang=en&sid=1 |
Similar Items
-
The role of anti-IgE (omalizumab/Xolair) in the management of severe recalcitrant paediatric atopic eczema (ADAPT): statistical analysis plan
by: Tao Chen, et al.
Published: (2017-05-01) -
Omalizumab (Xolair) in Children Above 12 Years With Chronic Urticaria: A Review of Literature
by: Javad Ghaffari, et al.
Published: (2015-01-01) -
Omalizumab (Xolair) in Children Above 12 Years With Chronic Urticaria: A Review of Literature
by: Javad Ghaffari, et al.
Published: (2015-01-01) -
Prevention of Atopic Dermatitis
by: Hywel C. Williams, et al.
Published: (2020-06-01) -
Effectiveness of omalizumab in a patient with severe asthma and atopic dermatitis
by: C. Incorvaia, et al.
Published: (2016-01-01)